CNDT Conduent Inc.

Conduent Launches Digital Solution to Help Pharmas with Faster and More Effective Product Commercialization

Conduent Launches Digital Solution to Help Pharmas with Faster and More Effective Product Commercialization

IntelliHealth module for healthcare provider engagement brings technology-driven virtual sales models for emerging and established pharma organizations

Analytics, AI, machine learning and experienced professionals enable hyper-personalized omnichannel engagement with healthcare professionals

FLORHAM PARK, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CNDT), a global technology-led business process solutions company, today announced the launch of the module for healthcare provider engagement. This new module is an end-to-end solution to help pharma organizations improve access to, and increase engagement with, healthcare professionals to drive focused pharmaceutical sales and marketing. IntelliHealth enables pharma organizations to power faster and more effective product commercialization with advanced analytics, omnichannel communication and experienced sales professionals and medical science liaisons. The robust platform delivers highly flexible hybrid engagement models that enable pharma organizations to reduce risk, manage costs and gain competitive advantages while driving ROI across the full life cycle of a drug therapy.

Pharma organizations are quickly adapting to the new normal where face-to-face contact to educate healthcare providers (HCPs) on established and emerging drug therapies has given way to remote interactions. The HCP now dictates when interactions occur across a variety of communications channels. IntelliHealth is built on state-of-the-art modular architecture and application programming interfaces that integrate with other third-party services to drive omnichannel engagement from drug launch to maturity with measurable outcomes across the product lifecycle. The next-generation technology is matched with the company’s proven experience in delivering emergent campaigns, via remote and digital engagement, to create a seamless experience for HCPs.

“Physicians and clinicians now determine when and how they engage, and new brands are quickly coming to market to increase competition across multiple therapy classes. Our pharma clients require HCP engagement models that advance their brands in a fast-changing and complex landscape,” said Randall King, President, Commercial Solutions at Conduent. “Hybrid commercialization models are now essential and the IntelliHealth module for healthcare provider engagement offers pharma leaders a complete, technology-enabled solution to customize, scale and execute their go-to-market strategies with enough agility to sustain long-term brand awareness.”

Conduent has helped pharma organizations launch and maintain brands for more than 30 years. The company serves seven of the 10 largest pharma and life sciences organizations with focused solutions including patient access services, hub programs, global medical information and sales and marketing services that span the product life cycle. Learn more at .

About Conduent

Conduent delivers mission-critical services and solutions on behalf of businesses and governments – creating exceptional outcomes for its clients and the millions of people who count on them. Through our dedicated people, processes, and technologies, Conduent solutions and services enhance customer experience, increase efficiencies, reduce costs, and improve performance for most Fortune 100 companies and more than 500 government entities. Whether it’s touching three out of every four health insured lives and delivering 45% of SNAP payments in the U.S., or enabling 1.3 billion customer service interactions and empowering 10 million employees through HR services worldwide, Conduent services and solutions interact with millions of people every day and move our clients’ operations forward. Learn more at .

Media Contact:

Sharon Lakes, Conduent, ,

Investor Relations Contact:

Giles Goodburn, Conduent, ,

Note: To receive RSS news feeds, visit . For open commentary, industry perspectives, and views, visit , or .

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.



EN
12/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Conduent Inc.

 PRESS RELEASE

Conduent Reports Second Quarter 2025 Financial Results

Conduent Reports Second Quarter 2025 Financial Results News from Conduent Key Q2 2025 Highlights Revenue and Adj. Revenue(1): $754MPre-tax Income (Loss): $(38)MAdj. EBITDA Margin(1): 4.9%New Business Signings ACV(2): $150MNet ARR Activity Metric(2) (TTM): $63M FLORHAM PARK, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Conduent Incorporated (Nasdaq: CNDT), a global technology-led business process solutions and services company, today announced its second quarter 2025 financial results. Cliff Skelton, Conduent President and Chief Executive Officer, stated, “Q2 marks another quarter of progre...

Conduent Inc: 1 director

A director at Conduent Inc bought 100,000 shares at 2.810USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

Conduent Reports First Quarter 2025 Financial Results

Conduent Reports First Quarter 2025 Financial Results Key Q1 2025 Highlights Revenue and Adj. Revenue(1): $751MPre-tax Income (Loss): $(56)MAdj. EBITDA Margin(1): 4.9%New Business Signings ACV(2): $109MNet ARR Activity Metric(2) (TTM): $116M FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Conduent Incorporated (Nasdaq: CNDT), a global technology-led business process solutions and services company, today announced its first quarter 2025 financial results. Cliff Skelton, Conduent President and Chief Executive Officer stated, “Conduent had a good start to 2025, especially amidst the ...

 PRESS RELEASE

Conduent Reports Fourth Quarter and Full Year 2024 Financial Results

Conduent Reports Fourth Quarter and Full Year 2024 Financial Results Key Q4 and Full Year 2024 Highlights Revenue: Q4 $800M / FY $3,356MAdj. Revenue(1): Q4 $800M / FY $3,176MPre-tax Income (Loss): Q4 $(82)M / FY $504MAdj. EBITDA Margin(1): Q4 4.0% / FY 3.9%New Business Signings ACV(2): Q4 $137M / FY $485MNet ARR Activity Metric(2) (TTM): $92M FLORHAM PARK, N.J., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Conduent Incorporated (Nasdaq: CNDT), a global technology-led business process solutions and services company, today announced its fourth quarter and full year 2024 financial results. Cliff Ske...

Conduent Incorporated: Credit profile pressured amid turnaround

Our credit view of this issuer reflects its very good liquidity, against its competitive challenges pressure operating performance.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch